JF
TARS icon

Jump Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

Jump Financial’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,600
Closed -$3.34M – 2453
2026
Q1 		$3.34M Sell
47,600
-80,487
-63% -$5.62M 0.04% 464
2025
Q4 		$10.5M Sell
128,087
-137,918
-52% -$10.3M 0.13% 194
2025
Q3 		$15.8M Buy
266,005
+28,888
+12% +$1.42M 0.19% 132
2025
Q2 		$9.61M Buy
237,117
+188,317
+386% +$8.47M 0.1% 250
2025
Q1 		$2.51M Buy
+48,800
New +$2.41M 0.03% 514
2024
Q4 		– Sell
-74,957
Closed -$2.47M – 2006
2024
Q3 		$2.47M Buy
+74,957
New +$2.11M 0.05% 438
2024
Q2 		– Sell
-29,470
Closed -$1.07M – 2249
2024
Q1 		$1.07M Buy
+29,470
New +$866K 0.03% 769
2022
Q4 		– Sell
-12,300
Closed -$211K – 2008
2022
Q3 		$211K Sell
12,300
-11,700
-49% -$186K 0.01% 1323
2022
Q2 		$350K Buy
+24,000
New +$360K 0.02% 1003

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jump Financial's TARS Position: Q2 2026 in Review

Jump Financial sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 47,600 shares — an estimated $3.34M sold.

Jump Financial first reported a position in TARS in Q2 2022 and held it in 9 quarters. The position peaked at $15.8M in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Jump Financial reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 47,600 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
  • Jump Financial first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 9 quarters.
  • Jump Financial's Tarsus Pharmaceuticals position peaked at $15.8M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.